Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes-focus on venlafaxine and O-desmethylvenlafaxine

European Journal of Clinical Pharmacology

Volumn 66, Issue 9, 2010, Pages 879-887

  Kandasamy, Mani ^a   Srinivas, P ^a   Subramaniam, Kala ^a   Ravi, Sandhya ^a   John, James ^a   Shekar, Radha ^a   Srinivas, Nuggehally ^b   Thangam, Saral ^a  

^a Lotus Labs Private Ltd   (India)

^b Integrated Drug Development   (India)

Author keywords

Bioavailability; CYP2D6; O desmethyvenlafaxine; Pharmacokinetics; Venlafaxine

Indexed keywords

CYTOCHROME P450 2D6; DESVENLAFAXINE; EFEXOR XR; UNCLASSIFIED DRUG; VENLAFAXINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG METABOLISM; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL DISTRIBUTION; NORMAL HUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; CYCLOHEXANOLS; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; INDIA; MALE; PHENOTYPE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; THERAPEUTIC EQUIVALENCY;

EID: 77956189817     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0829-y     Document Type: Article

References (33)

1. A Khan LF Fabre R Rudolph 1991 Venlafaxine in depressed outpatients Psychopharmacol Bull 27 141 144 1:STN:280:DyaK38%2FitFemtw%3D%3D 1924660
2. E Schweizer C Weise C Clary K Rickels 1991 Placebo-controlled trial of venlafaxine for the treatment of major depression J Clin Psychopharmacol 11 233 236 10.1097/00004714-199108000-00002 1:STN:280:DyaK38%2Fht1artg%3D%3D 1918421
3. EA Muth JT Haskins JA Moyer GEM Husbands ST Nielsen EB Sigg 1986 Antidepressant biochemical profile of the novel bicyclic compound Wy-45, 030, an ethyl cyclohexanol derivative Biochem Pharmacol 35 4493 4497 10.1016/0006-2952(86)90769-0 1:CAS:528:DyaL2sXpsF2ksw%3D%3D 3790168
4. EA Muth JA Moyer JT Haskins TH Andree GEM Husbands 1991 Biochemical, neurophysiological, and behavioral effects of Wy-45233, its enantiomers, and other identified metabolites of the antidepressant venlafaxine Drug Dev Res 23 191 199 10.1002/ddr.430230210 1:CAS:528:DyaK3MXkvVGht7k%3D
5. SR Howell GE Husbands JA Scatina SF Sisenwine 1993 Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man Xenobiotica 23 349 359 10.3109/00498259309057023 1:CAS:528:DyaK3sXlvFGjtrk%3D 8337893
6. LF Fabre HP Putman 1987 An ascending single-dose tolerance study of Wy-45, 030, a bicyclic antidepressant, in healthy men Curr Ther Res 42 901 909 1:CAS:528:DyaL1cXjtFalsA%3D%3D
7. KJ Klamerus K Maloney RL Rudolph SF Sisenwine WJ Jusko ST Chiang 1992 Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite J Clin Pharmacol 32 716 724 1:STN:280:DyaK3s7jvFaqsQ%3D%3D 1487561
8. SM Troy VD Parker RJ Fruncillo ST Chiang 1995 The pharmacokinetics of venlafaxine when given in a twice daily regimen J Clin Pharmacol 35 404 409 1:CAS:528:DyaK2MXlslCrtL4%3D 7650231
9. CB Eap E Lessard P Baumann, et al. 2003 Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans Pharmacogenetics 13 39 47 10.1097/00008571-200301000-00006 1:CAS:528:DC%2BD3sXlsFGqsg%3D%3D 12544511
10. CB Eap R Bertel-Laubscher D Zullino M Amey P Baumann 2000 Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report Pharmacopsychiatry 33 112 115 10.1055/s-2000-7975 1:STN:280:DC%2BD3cvnsVCqsg%3D%3D 10855463
11. T Fakuda Y Nishida O Zhou I Yamamoto S Kondo J Azuma 2000 The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population Eur J Clin Pharmacol 56 175 180 10.1007/s002280050737
12. E Lessard MA Yessine BA Hamelin G O'Hara J leBlanc J Turgeon 1999 Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans Pharmacogenet 9 435 443 10.1097/00008571-199912000-00003 1:CAS:528:DyaK1MXmtlGjsrY%3D
13. T Fukuda I Yamamoto Y Nishida Q Zhou M Ohno K Takada J Azuma 1999 Effect of CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers Br J Clin Pharmacol 47 450 453 10.1046/j.1365-2125.1999.00913.x 1:CAS:528:DyaK1MXivVCmtLs%3D 10233212
14. Kandasamy M, Tripathy K, Ravi S, Kamath N, Pai B, Srinivas NR, Kristjansson F, Thangam S (2010) Unsuspected poor metabolizer phenotypes of fluoxetine in bioavailability/bioequivalence studies from an Indian population perspective-retrospective pharmacokinetic data evaluation. Arzniemittelforsch Drug Res 60(1):12-21
15. K Goryachkina A Burbello S Boldueva S Babak U Bergman L Bertilsson 2008 CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction Eur J Clin Pharmacol 64 1163 1173 10.1007/s00228-008-0525-3 1:CAS:528:DC%2BD1cXhsVCktLrK 18648788
16. BJ Davies MK Herbert JK Coller AA Somogyi RW Milne BC Sallustio 2008 Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline Br J Clin Pharmacol 65 347 354 10.1111/j.1365-2125.2007.03015.x 1:CAS:528:DC%2BD1cXkvFOrsLY%3D 17875193
17. UM Stamer F Musshoff M Kobilay B Madea A Hoeft F Stuber 2007 Concentrations of tramadol and O-desmethyltramadol enantiomers in different CYP2D6 genotypes Clin Pharmacol Ther 82 41 47 10.1038/sj.clpt.6100152 1:CAS:528:DC%2BD2sXotVGju7o%3D 17361124
18. CB Eap F Broly A Mino, et al. 2001 Cytochrome P450 2D6 genotype and methadone steady-state concentrations J Clin Psychopharmacol 21 229 234 10.1097/00004714-200104000-00016 1:CAS:528:DC%2BD3MXisV2qsbo%3D 11270921
19. WD Paar S Poche J Gerloff HJ Dengler 1997 Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol Eur J Clin Pharmacol 53 235 239 10.1007/s002280050368 1:CAS:528:DyaK2sXnvVensLY%3D 9476037
20. S Preskorn A Patroneva H Silma, et al. 2009 Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers J Clin Psychopharmacol 29 39 43 10.1097/JCP.0b013e318192e4c1 19142106
21. M Hermann M Hendset K Fosaas M Hierpset H Refsum 2008 Serum concentrations of venlafaxine and its metabolite O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3,*4 or*5 allele Eur J Clin Pharmacol 64 483 487 10.1007/s00228-007-0453-7 1:CAS:528:DC%2BD1cXjsVCrtbg%3D 18214456
22. ME Shams B Arneth C Hiemke, et al. 2006 CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine J Clin Pharm Ther 31 493 502 10.1111/j.1365-2710.2006.00763.x 1:CAS:528:DC%2BD28XhtF2mu7rK 16958828
23. Bolton S, Bon C (2004) Pharmaceutical statistics: practical and clinical applications, 4th ed. Marcel Dekker, New York
24. E Spina V Santoro C D'Arrigo 2008 Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update Clin Ther 30 1206 1227 10.1016/S0149-2918(08)80047-1 1:CAS:528:DC%2BD1MXltVyitL8%3D 18691982
25. JS Oliver GD Burrows TR Norman 2004 The treatment of depression with different formulations of venlafaxine: a comparative analysis Hum Psychopharmacol 19 9 16 10.1002/hup.551
26. JD Lindh A Annas L Meurling ML Dahl A Al-Shurbaji 2003 Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine Eur J Clin Pharmacol 59 401 406 10.1007/s00228-003-0627-x 1:CAS:528:DC%2BD3sXnt1Kitrc%3D 12898080
27. CB Eap E Lessard P Baumann, et al. 2003 Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans Pharmacogenetics 13 39 47 10.1097/00008571-200301000-00006 1:CAS:528:DC%2BD3sXlsFGqsg%3D%3D 12544511
28. DE McAlpine DJ O'Kane JL Black DA Mrazek 2007 Cytochrome P450 2D6 genotype variation and venlafaxine dosage Mayo Clin Proc 82 1065 1068 10.4065/82.9.1065 1:CAS:528:DC%2BD2sXhtV2rt7%2FK 17803873
29. SM Troy VP Parker DR Hicks GM Pollack ST Chiang 1997 Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine J Clin Pharmacol 37 954 961 1:CAS:528:DyaK2sXnsVyjsbc%3D 9505987
30. A Patat S Troy J Burke, et al. 1996 Absolute bioavailability and electroencephalographic effects of conventional and extended release formulations of venlafaxine in healthy subjects J Clin Pharmacol 38 256 267
31. SM Troy I Lucki AA Pergies VD Parker PM Klockowski ST Chiang 1995 Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam J Clin Pharmacol 35 410 419 1:CAS:528:DyaK2MXlslCrtL8%3D 7650232
32. SF Zhou 2009 Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I Clin Pharmacokinet 48 689 723 10.2165/11318030-000000000- 00000 1:CAS:528:DC%2BD1MXhsFOmt7rP 19817501
33. AI Nichols K Lobello CJ Guico-Pabia J Paul SH Preskorn 2009 Venlafaxine metabolism as a marker of cytochrome P450 enzyme 2D6 metabolizer status J Clin Psychopharmacol 29 383 386 10.1097/JCP.0b013e3181acc4dd 1:CAS:528: DC%2BD1MXotlOkuro%3D 19593180